hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06342258 id: HS-23-00611 briefTitle: COES: Curing Order Effects on Sealants acronym: COES overallStatus: RECRUITING date: 2024-02-23 date: 2026-06-30 date: 2026-06-30 date: 2024-04-02 date: 2024-04-11 name: University of Southern California class: OTHER briefSummary: Background: Sealants are a great tool in the prevention of caries in the pediatric population. It has been shown that up to 71% of occlusal decay is preventable after a single sealant application in a fissure, and thus is the standard of care due to difficulty for pediatric patients in hygiene, diet, and overall home care until manual dexterity increases.
Methods: A split mouth prospective randomized control study will be performed on pediatric dental patients at Long Beach Memorial's Children's Dental Health Clinic and USC Pediatric Dental Clinic, placing sealants with cured bond on half of a mouth and sealants with uncured bond on the contralateral half. Intraoral photos will be obtained at the initial visit and recalls to evaluate the overall retention/longevity of the sealant placement. The goal of this study is determine which sealant has higher longevity and to provide recommendations for future pediatric dentists regarding sealant procedures. conditions: Dental Sealant conditions: Sealant Retention studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: After baseline examination, a randomized generator, will be used in order to issue which side will bonding agent cured prior to sealant placement. Randomization will be a simple randomization, and will be determined by the provider flipping a coin. Randomization will be performed to ensure graders of sealants will be blinded to which side of bond is cured prior to sealant placement.
Tails indicates the LEFT side of the mouth WILL be cured prior to sealant placement. The right side of the mouth will not have bond cured prior to sealant placement. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 217 type: ESTIMATED name: Ultradent Ultra Seal XT Plus measure: Sealant Longevity measure: Caries measure: Molar hypomineralization sex: ALL minimumAge: 5 Years maximumAge: 14 Years stdAges: CHILD facility: Herman Ostrow School of Dentistry of USC status: RECRUITING city: Los Angeles state: California zip: 90089 country: United States name: Catherine Pham, DDS, MPH role: CONTACT phone: 213-740-0412 email: cmpham@usc.edu lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06342245 id: 2023.568 briefTitle: Low-temperature Radiofrequency Coblation Micro-tenotomy for the Treatment of Achilles Tendinopathy acronym: AT RCT overallStatus: NOT_YET_RECRUITING date: 2024-06-11 date: 2027-06-10 date: 2027-06-11 date: 2024-04-02 date: 2024-04-02 name: Chinese University of Hong Kong class: OTHER briefSummary: This is a prospective randomized, double-blinded, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio to investigate the effectiveness of radiofrequency coblation micro-tenotomy for patients with Achilles tendinopathy. All participants will be randomized into two groups: the intervention group (n=24; radiofrequency coblation micro-tenotomy + endoscopic Achilles debridement) and the control group (n=24; endoscopic Achilles debridement only). Adults (age \>18) with clinically diagnosed midportion Achilles tendinopathy will be recruited and scheduled for ultrasound screening. All participants will undergo a 12-week eccentric exercise program taught by a registered physiotherapist / athletic trainer. Undergo Endoscopic Achilles debridement and Radiofrequency coblation micro-tenotomy intervention. Criteria for discontinuing or modifying allocated interventions, Strategies to improve adherence to interventions, Relevant concomitant care permitted or prohibited during the trial and Provisions for post-trial care. Outocme measure will use VISA-A, pain scores, ultrasound measurement of thickness and vascularity, calf muscle strength, and ankle range of motion. conditions: Achilles Tendinopathy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a multicentre prospective randomized, double-blinded, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio to investigate the effectiveness of radiofrequency coblation micro-tenotomy for patients with Achilles tendinopathy. All participants will be randomized into two groups: the intervention group (n=24; radiofrequency coblation micro-tenotomy + endoscopic Achilles debridement) and the control group (n=24; endoscopic Achilles debridement only).
nctId: NCT06342232 id: BEH1986 id: 423629 type: OTHER_GRANT domain: Saskatchewan Health Research Foundation briefTitle: The Efficacy of Neurofeedback Mindfulness in Migraine Management overallStatus: COMPLETED date: 2021-09-09 date: 2022-12-24 date: 2023-03-01 date: 2024-04-02 date: 2024-04-02 name: University of Saskatchewan class: OTHER name: Saskatchewan Health Research Foundation briefSummary: This longitudinal randomized controlled trial explored how long-term practice of neurofeedback mindfulness would be helpful for migraine management when compare dot a similar controlled intervention. All the participants went through assigned 10 minutes practices on a daily basis for 8 weeks. Behavioural reports and migraine characteristics were compared before and after the intervention. conditions: Migraine Headaches studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 101 type: ACTUAL name: Neurofeedback mindfulness name: Simple attention controlled task measure: Migraine Disability measure: Migraine Severity measure: Headache Management Self-efficacy measure: Anxiety measure: Depression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Saskatchewan city: Saskatoon state: Saskatchewan zip: S7N5A2 country: Canada lat: 52.13238 lon: -106.66892 hasResults: False
nctId: NCT06342219 id: 423629 briefTitle: Chronic Migraines and Neurofdeeback Mindfulness overallStatus: NOT_YET_RECRUITING date: 2024-12 date: 2025-12 date: 2026-06 date: 2024-04-02 date: 2024-04-02 name: University of Saskatchewan class: OTHER name: Saskatchewan Health Research Foundation briefSummary: As the second phase of our study on migraine headaches and neurofeedback mindfulness, we will explore how chronic migraineurs will benefit from a long term practice (8 weeks) of neurofeedback mindfulness compared to a similar attention group and a waitlisted group. This randomized controlled trial will also explore if migrianuers could decrease their dependence on medicine intake after completion of the study. conditions: Chronic Migraine, Headache studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 135 type: ESTIMATED name: Neurofeedback Mindfulness name: Attention Task measure: Migraine Disability measure: Migraine Severity measure: Headache management self-efficacy measure: Dependence on medicine measure: Anxiety measure: Depression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Saskatchewan city: Saskatoon state: Saskatchewan zip: S7N5A2 country: Canada lat: 52.13238 lon: -106.66892 hasResults: False
nctId: NCT06342206 id: CMUH111-REC2-144 briefTitle: The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools overallStatus: RECRUITING date: 2022-09-08 date: 2022-09-21 date: 2024-09-07 date: 2024-04-02 date: 2024-04-02 name: China Medical University Hospital class: OTHER briefSummary: Cerebral infarction is the second cause of death and the third cause of disability. More than 13.7 million patients worldwide are diagnosed with stroke every year, and the number of deaths is 5.5 million, of which ischemic stroke is the major type, accounting for 87%. Sequelae of stroke are problems that require long-term medical care. If we can intervene and assist with Traditional Chinese Medicine (TCM) at early stage, it will be a great boon for patients. In clinical practice, TCM collects data as the basis for diagnosis through the four diagnostic methods-look, listen, question, and feel the pulse. Among these, tongue diagnosis and pulse diagnosis belong to the categories of look and feel the pulse. At present, the objective examination instruments of TCM developed are mainly tongue diagnostic instruments and pulse diagnostic instruments. Therefore, we hope to utilize tongue and pulse diagnoses as the main reference to analyze the changes in ischemic stroke stages. The data of this study are collected from China Medical University Hospital and YuanRung Hospital-for further statistical analysis. Ischemic stroke patients (ICD-10: I63) who were hospitalized within 1 week from the date of diagnosis were eligible to join this research project. Tongue and pulse examinations were collected once per week within 1 month. A total of 4 tongue-pulse examinations were collected in each case, which were categorized into acute stage (24 hours to 1 week), subacute stage (1 to 3 weeks) and chronic stage (more than 3 weeks). \[30\] This research is to study the changes of tongue and pulse diagnoses in acute, subacute and chronic stages among ischemic patients who receive TCM diagnosis and treatment. Through utilizing objective evaluation of Chinese and Western medical examination instruments, we hope to establish clear diagnostic standards for TCM syndrome types, so as to evaluate the efficacy of clinical diagnosis and treatment. The goal is to improve the quality of TCM care and to provide Chinese and Western integrated treatment for stroke patients in the future. This research can also serve as a reference for related TCM research and development. conditions: Stroke, Ischemic studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 24 type: ESTIMATED measure: Differences between tongue diagnosis and pulse diagnosis in acute and chronic stroke patients sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: YuanRung Hospital status: RECRUITING city: Changhua zip: 510 country: Taiwan name: LI-CHI TSAI role: CONTACT phone: 0919688481 name: YEN-HUA YANG role: CONTACT phone: 0912587467 lat: 24.07327 lon: 120.56276 hasResults: False
nctId: NCT06342193 id: virtual reality briefTitle: Effect of Virtual Reality Glasses on Anxiety During Cystoscopy: A Randomised Controlled Trial overallStatus: RECRUITING date: 2024-03-14 date: 2024-06-15 date: 2024-06-15 date: 2024-04-02 date: 2024-04-02 name: Uşak University class: OTHER briefSummary: The aim of this study was to investigate the effect of using virtual reality glasses as a distraction method on anxiety in men undergoing cystoscopy under local anaesthesia. conditions: Cystoscopy conditions: Virtual Reality conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: virtual reality group measure: anxiety sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Usak Training and Research Hospital status: RECRUITING city: Uşak state: Center zip: 64100 country: Turkey name: Yucel Can Danisman role: CONTACT phone: +905532864569 email: 202201023@ogr.usak.edu.tr name: Fatma Susam, PhD role: SUB_INVESTIGATOR name: Yucel Can Danisman role: PRINCIPAL_INVESTIGATOR name: Ozan Ozavci role: SUB_INVESTIGATOR name: Shahnaza Mahmudova role: SUB_INVESTIGATOR name: Erkan Arslan, MD role: SUB_INVESTIGATOR name: Adem Tuncekin, MD role: SUB_INVESTIGATOR name: Bilgen Arikan, PhD role: PRINCIPAL_INVESTIGATOR lat: 38.67351 lon: 29.4058 hasResults: False
nctId: NCT06342180 id: Usakupcos1 briefTitle: Metabolic Differences Between Subtypes of Polycystic Ovary Syndrome overallStatus: COMPLETED date: 2022-01-01 date: 2022-09-01 date: 2023-07-20 date: 2024-04-02 date: 2024-04-02 name: Uşak University class: OTHER briefSummary: We aimed to investigate serum uric acid levels in patients with different phenotype of policystic ovary syndrome and to compare healthy controls. conditions: Uric Acid Concentration, Serum, Quantitative Trait Locus 7 conditions: Polycystic Ovary Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 300 type: ACTUAL name: Serum uric acid level measure: Uric acid levels in PCOS subtypes sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Usak Egitim Ve Araştırma Hastanesi city: Uşak zip: 64100 country: Turkey lat: 38.67351 lon: 29.4058 hasResults: False
nctId: NCT06342167 id: NCC4409 briefTitle: Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-14 date: 2026-07-01 date: 2026-12-01 date: 2024-04-02 date: 2024-04-03 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER briefSummary: At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status. However, cCRT has substantial toxic effects, and a large number of patients with older age, malnutrition and other morbidities, cannot tolerate cCRT. Several phase II trials showed combining PD-1 inhibitor with definitive cCRT provided encouraging activity and acceptable toxicity in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC).
Therefore, this single-arm, multicenter, phase II trial aims to assess the efficacy and safety of immunotherapy plus radiotherapy with immunonutrition support in patients with LA-ESCC and positive PD-L1 expression who are intolerant to cCRT. conditions: Locally Advanced Esophageal Squamous Cell Carcinoma conditions: Sintilimab conditions: Radiotherapy conditions: Concurrent Chemoradiotherapy conditions: Immunonutrition studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 57 type: ESTIMATED name: Radiotherapy name: Programmed Cell Death Protein 1 Inhibitor name: Immunonutrition support measure: 1-year Progression-free survival rate (PFS) measure: Objective response rate measure: Progression-free survival measure: Overall survival rate measure: Overall survival measure: Incidence of adverse events sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College city: Beijing state: Beijing zip: 100021 country: China lat: 39.9075 lon: 116.39723 facility: Department of Radiation Oncology，Clinical Oncology School of Fujian Medical University，Fujian Cancer Hospital city: Fujian state: Fujian country: China facility: Department of Oncology, Affiliated Hospital, Hebei University of Engineering city: Handan state: Hebei country: China lat: 36.60056 lon: 114.46778 facility: Department 1st of Radiation Oncology, Anyang Tumor Hospital city: Anyang state: Henan country: China lat: 36.096 lon: 114.38278 facility: Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University city: Xinxiang state: Henan country: China lat: 35.19033 lon: 113.80151 facility: Department of Radiation Oncology, General Hospital of Ningxia Medical University city: Yinchuan state: Ningxia country: China lat: 38.46806 lon: 106.27306 facility: Department of Radiation Oncology，Fei County People's Hospital city: Feixian state: Shandong country: China facility: Department of Radiation Oncology, Affiliated hospital of Jining Medical University city: Jining state: Shandong country: China lat: 35.405 lon: 116.58139 facility: Taizhou hospital of Wenzhou Medical University city: Taizhou state: Zhejiang zip: 317000 country: China lat: 32.49069 lon: 119.90812 hasResults: False
nctId: NCT06342154 id: MCBU-SBF-YC-03 briefTitle: Does Endorphin Massage Reduce the Anxiety of Pregnant Women? overallStatus: RECRUITING date: 2023-10-09 date: 2024-10-09 date: 2024-12-10 date: 2024-04-02 date: 2024-04-02 name: Celal Bayar University class: OTHER briefSummary: Before cesarean section surgery, researchers will demonstrate endorphin massage to the husbands of pregnant women, and they will be asked to apply the massage before the surgery. The stress levels and pain levels of women will be compared before and after the massage. conditions: Pregnancy Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized study with experimental and control group primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 68 type: ESTIMATED name: Endorphin Massage measure: visual analog scale (VAS) measure: State and Trait Anxiety Scales measure: cortisol level sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Manisa Celal Bayar Üniversitesi Hafsa Sultan Hastanesi status: RECRUITING city: Manisa zip: 45060 country: Turkey lat: 38.61202 lon: 27.42647 hasResults: False
nctId: NCT06342141 id: 24-1423 briefTitle: Empagliflozin for No-reflow Phenomenon in PCI for STEMI acronym: EMPA-PCI overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-01-15 date: 2025-03-15 date: 2024-04-02 date: 2024-04-02 name: Instituto Nacional de Cardiologia Ignacio Chavez class: OTHER briefSummary: Myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. A significant contributor to this issue is reperfusion injury, which enlarges the infarction, deteriorates ventricular function, leads to poorer outcomes, and currently has no specific treatment. Originally developed as an antidiabetic, empagliflozin has shown significant benefits in other organs and systems. Recent years have seen the demonstration of its cellular and vascular effects in animal models, potentially contributing to the reduction of reperfusion damage. However, no human studies have yet confirmed these effects.
The primary outcome will be the incidence of the no-reflow phenomenon, measured through the Thrombolysis in Myocardial infarction (TIMI) flow scale in the coronary angiography performed to treat the infarction. Secondary outcomes will include the reduction of ST segment on the electrocardiogram, troponin levels, differences in the longitudinal strain by echocardiogram, and infarct size by magnetic resonance imaging. conditions: STEMI conditions: No-Reflow Phenomenon studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 162 type: ESTIMATED name: Empagliflozin 25 milgrams (Mg) name: Empagliflozin 10 Mg name: Placebo 25 Mg name: Placebo 10 Mg measure: Non-Reflow Phenomenon measure: Infract size measure: Longitudinal Strain measure: High-sensitivity Troponin Clearance measure: Creatine Kinase-myocardial band Clearance measure: Adverse Cardiovascular Events sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342128 id: MVI_Kidney_001 briefTitle: Molecular Landscape of Microvascular Inflammation in Kidney Allografts overallStatus: RECRUITING date: 2022-01-01 date: 2024-06 date: 2024-12 date: 2024-04-02 date: 2024-04-03 name: Paris Translational Research Center for Organ Transplantation class: OTHER briefSummary: Microvascular inflammation in kidney allografts has been widely reappraised in the recent update of Banff classification. There is a critical need to better understand the pathophysiological mechanisms associated with the various phenotypes of microvascular inflammation that are observed in kidney transplants, particularly in order to develop targeted therapeutic approaches. conditions: Kidney Rejection Transplant studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: No intervention measure: RNA-based molecular signatures assessed using bulk and spatial transcriptomics measure: Probability of graft survival based on outcome data measure: Probability of patient survival on outcome data sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris status: RECRUITING city: Paris zip: 75010 country: France name: Carmen Lefaucheur, MD PhD role: CONTACT email: carmen.lefaucheur@aphp.fr lat: 48.85341 lon: 2.3488 facility: Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris status: RECRUITING city: Paris zip: 75015 country: France name: Alexandre Loupy, MD PhD role: CONTACT phone: +33612491082 email: alexandreloupy@inserm.fr lat: 48.85341 lon: 2.3488 facility: Bichat Hospital, Assistance Publique - Hôpitaux de Paris status: RECRUITING city: Paris zip: 75018 country: France name: Aurélie Sannier, MD PhD role: CONTACT email: aurelie.sannier@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06342115 id: CLEMENT TRIAL briefTitle: Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens acronym: CLEMENT overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-04 date: 2025-04 date: 2024-04-02 date: 2024-04-02 name: Beneficência Portuguesa de São Paulo class: OTHER name: Merck Sharp & Dohme LLC briefSummary: The study proposes a planned, double-blind, non-inferiority clinical trial involving patients with febrile neutropenia and risk of extended-spectrum beta-lactamase (ESBL) infection. The goal is:
Patients will be randomly assigned to receive CEF/TAZ or meropenem, with assessment of clinical response, toxicity and microbiological evolution. Stool samples will be collected before, during and after treatment for intestinal microbiota analysis and intestinal microbiome analysis to evaluate possible effects on GVHD. Analysis of the results will include the taxonomic classification of the organisms present. Data will be analyzed to assess non-inferiority in clinical response, incidence of GVHD, antimicrobial resistance and other outcomes. conditions: Febrile Neutropenia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 176 type: ESTIMATED name: Ceftolozane-Tazobactam name: Meropenem measure: Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population measure: Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population measure: Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population measure: Incidence of microbiologically documented infections and identification of causative organisms in culture measure: In-hospital mortality measure: Occurrence of graft versus host disease (GVHD) measure: Frequency of multidrug resistant-pathogen infections or colonization measure: Faecal microbiota analysis measure: Percentage of Participants Who Report 1 or More Adverse Event (AE) measure: Percentage of Participants With Any Serious Adverse Event (SAE) measure: Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: A Beneficência Portuguesa de São Paulo city: São Paulo country: Brazil name: João Prats, MD role: CONTACT phone: +55 11 3505 5031 lat: -23.5475 lon: -46.63611 hasResults: False